Cargando…
Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia
SIMPLE SUMMARY: Infusions of T-cells genetically modified to recognize the protein CD19 (CD19 CAR-T cells) have proven a potent form of cancer therapy for certain cancers arising from B-cells. These treatments, while revolutionary, remain expensive to manufacture using a patients’ own cells and can...
Autores principales: | Gurney, Mark, O’Dwyer, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036691/ https://www.ncbi.nlm.nih.gov/pubmed/33805422 http://dx.doi.org/10.3390/cancers13071568 |
Ejemplares similares
-
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
por: Albinger, Nawid, et al.
Publicado: (2022) -
Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia
por: Lipof, Jodi J., et al.
Publicado: (2018) -
CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022) -
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019) -
NK cell defects: implication in acute myeloid leukemia
por: D’Silva, Selma Z., et al.
Publicado: (2023)